TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8919573

Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Unilateral ECT
Number of subjects: 92

Group type: COMPARATOR
Intervention: Low dosage ECT
Number of subjects: 92

Group type: COMPARATOR
Intervention: High dosage ECT
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: ECT course
Number of subjects: 92
Study: 2186630

Group type: EXPERIMENTAL
Intervention: ancrod 0.5 mu/kg in normal saline administered as a constant-rate intravenous infusion over 6 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 20
Study: 109596

Group type: EXPERIMENTAL
Intervention: Glucose plus 2.5 gm/kg of amino acids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose alone
Number of subjects: 0
Study: 29188471

Group type: EXPERIMENTAL
Intervention: Brilliant Blue G (BBG)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Trypan Blue (TB)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 117
Study: 28545756

Group type: EXPERIMENTAL
Intervention: Safe Alternatives for Teens and Youths (SAFETY)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (E-TAU)
Number of subjects: 0
Study: 26063508

Group type: EXPERIMENTAL
Intervention: Vitamin D3 2.4 mg once every 2 months + 10 μg daily for residents, 3 mg once every 2 months for carers
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo once every 2 months + vitamin D3 10 μg daily for residents, placebo once every 2 months for carers
Number of subjects: 240
Study: 23860103

Group type: EXPERIMENTAL
Intervention: Active electrical stimulation therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 54
Study: 20451663

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg induction at weeks 0, 2, and 4; maintenance therapy randomized to every 2 weeks or every 4 weeks.
Number of subjects: 539

Group type: COMPARATOR
Intervention: Certolizumab pegol 400 mg every 4 weeks maintenance therapy.
Number of subjects: 539

Group type: COMPARATOR
Intervention: Certolizumab pegol 400 mg every 2 weeks maintenance therapy.
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Induction therapy with certolizumab pegol.
Number of subjects: 539

Group type: COMPARATOR
Intervention: Maintenance therapy with certolizumab pegol.
Number of subjects: 539
Study: 18771834

Group type: EXPERIMENTAL
Intervention: Standard implementation intentions with protection motivation-based information
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Reasoning implementation intentions with protection motivation-based information
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard implementation intentions without protection motivation-based information
Number of subjects: 210

Group type: COMPARATOR
Intervention: Reasoning implementation intentions without protection motivation-based information
Number of subjects: 210
Study: 16868453

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: fluvastatin 80 mg/day
Number of subjects: 20
Study: 12796126

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 10666136

Group type: EXPERIMENTAL
Intervention: Intraduodenal fructose (25%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose (25%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 10
Study: 8852391

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 1523108

Group type: EXPERIMENTAL
Intervention: Social cognitive theory AIDS prevention intervention
Number of subjects: 109
Study: 6377803

Group type: EXPERIMENTAL
Intervention: Nimodipine 120 mg orally as 3 divided doses
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 60
Study: 31212365

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 125

Group type: COMPARATOR
Intervention: 40 mg atorvastatin
Number of subjects: 125
Study: 29425373

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss program
Number of subjects: 450
Study: 27529510

Group type: EXPERIMENTAL
Intervention: ALLN-177 treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study: 23952962

Group type: EXPERIMENTAL
Intervention: Probiotics (mixture of Bifidobacterium longum, Lactobacillus bulgaricus and Streptococcus thermophilus) three times per day for 4 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (oral local antifungal agents alone: gargle 2% sodium bicarbonate solution for 30 s, wait 10 min and then apply 2% nystatin paste)
Number of subjects: 65
Study: 22954164

Group type: EXPERIMENTAL
Intervention: SPARK program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 20091310

Group type: EXPERIMENTAL
Intervention: Transperineal repair with levatorplasty (TPR‐LP)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Transperineal repair without levatorplasty (TPR)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Transanal repair (TAR)
Number of subjects: 48
Study: 17397435

Group type: EXPERIMENTAL
Intervention: Oral desmopressin (ddAVP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 17719472

Group type: EXPERIMENTAL
Intervention: Torasemide (10 to 20 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Furosemide (20 to 40 mg/day)
Number of subjects: 22
Study: 14764771

Group type: EXPERIMENTAL
Intervention: PUFA-rich diet
Number of subjects: 17
Study: 10836283

Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg/day (days 1-4), 150 mg/day (days 5-10), 225 mg/day (days 11-42)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day (days 1-4), 40 mg/day (days 5-10), 60 mg/day (days 11-42)
Number of subjects: 109
Study: 9096088

Group type: EXPERIMENTAL
Intervention: Technetium-99m labelled monoclonal antibody (MAb) 170H.82 at protein doses of 1, 2 and 4 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Technetium-99m labelled monoclonal antibody (MAb) 170H.82 at 2 mg dose
Number of subjects: 53
Study: 8362758

Group type: EXPERIMENTAL
Intervention: High counter height (35.5 inches) with near queuing area
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High counter height (35.5 inches) with far queuing area
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low counter height (31.5 inches) with near queuing area
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low counter height (31.5 inches) with far queuing area
Number of subjects: 42
Study: 2938984

Group type: EXPERIMENTAL
Intervention: Nafarelin acetate, D‐Nal(2)6‐GnRH, administered intranasally in a daily dose of 125 micrograms to 25 women.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Nafarelin acetate, D‐Nal(2)6‐GnRH, administered intranasally in a daily dose of 250 micrograms to 22 women.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Nafarelin acetate, D‐Nal(2)6‐GnRH, both doses (125 and 250 micrograms).
Number of subjects: 47
Study: 30758167

Group type: EXPERIMENTAL
Intervention: Adaptive neuro-stimulation (ANS) with 2 pre-set programs, 4 times a week using an ENF Physio® device (15-350 Hz)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (device switched off)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adaptive neuro-stimulation (ANS)
Number of subjects: 20
Study: 27651055

Group type: EXPERIMENTAL
Intervention: Podcast learning
Number of subjects: 130

Group type: COMPARATOR
Intervention: Text learning
Number of subjects: 130
Study: 25031187

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral therapy (ICBT)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (GCBT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Web-based discussion forum (DF)
Number of subjects: 128
Study: 24337491

Group type: EXPERIMENTAL
Intervention: Dual-energy computed tomography (DECT) with sagittal oblique displays (mixed kV soft tissue, SE bone removal, and DECT bone removal)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dual-energy computed tomography (DECT) with oblique sagittal reconstructions
Number of subjects: 27

Group type: COMPARATOR
Intervention: Other techniques (not specified)
Number of subjects: 27
Study: 22206075

Group type: EXPERIMENTAL
Intervention: RT001 Botulinum Toxin Type A Topical Gel
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 20183681

Group type: EXPERIMENTAL
Intervention: Psychosocial interventions focusing on stress and coping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 17565914

Group type: EXPERIMENTAL
Intervention: Ropivacaine administered pre‐incisionally and intraperitoneally (Group 1, n=14)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ropivacaine administered pre‐incisionally and intraperitoneally (Group 2, n=17)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ropivacaine administered intraperitoneally and locally at incision sites (Group 3, n=14)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 45
Study: 15019739

Group type: EXPERIMENTAL
Intervention: Cranberry-containing mouthwash (NDM)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 59
Study: 11450599

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with cat epithelial extract
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9486679

Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 108
Study: 7850540

Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Doxorubicin 90 mg/m2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Doxorubicin 120 mg/m2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Complete hepatic venous isolation and extracorporeal chemofiltration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hepatic and systemic MTD of doxorubicin
Number of subjects: 10
Study: 3049403

Group type: EXPERIMENTAL
Intervention: Intravenous, followed by oral, metoprolol
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 129
Study: 31181631

Group type: EXPERIMENTAL
Intervention: EAT5 FFQ
Number of subjects: 100
Study: 27807281

Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment in patients on prior antiplatelet treatment
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment in patients not on prior antiplatelet treatment
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Successful reperfusion in patients on prior antiplatelet treatment
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Successful reperfusion in patients not on prior antiplatelet treatment
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Symptomatic intracranial hemorrhage in patients on antiplatelet treatment
Number of subjects: 500

Group type: COMPARATOR
Intervention: Symptomatic intracranial hemorrhage in patients without antiplatelet treatment
Number of subjects: 500
Study: 26194461

Group type: EXPERIMENTAL
Intervention: Standard care plus NP-delivered symptom management intervention (proactive telephone calls during the week after each of the first 2 chemotherapy visits)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 120
Study: 23564803

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 537
Study: 22484874

Group type: EXPERIMENTAL
Intervention: Composite resin (34% Tooth Conditioner Gel + Adper Single Bond 2 + Z100)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bonded amalgam (34% Tooth Conditioner Gel + Prime and Bond 2.1 + Permite C)
Number of subjects: 30
Study: 19486950

Group type: EXPERIMENTAL
Intervention: Intravesical mytomicin-c chemotherapy after surgical resection
Number of subjects: 0
Study: 17112851

Group type: EXPERIMENTAL
Intervention: Corticosteroids at usual doses (Group A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Corticosteroids at 50% lower doses (Group B)
Number of subjects: 150
Study: 15206528

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noninferiority trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noninferiority test procedure
Number of subjects: 0
Study: 12622457

Group type: EXPERIMENTAL
Intervention: Boswellia serrata Extract (BSE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10859288

Group type: COMPARATOR
Intervention: 325 mg ASA daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 325 mg ASA + 75 mg clopidogrel daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 325 mg ASA daily + 300 mg clopidogrel loading dose on day 1 and +75 mg clopidogrel per day on days 2 to 10
Number of subjects: 18
Study: 9191583

Group type: EXPERIMENTAL
Intervention: Caffeine during 64 hours of sleep deprivation
Number of subjects: 0
Study: 1528095

Group type: EXPERIMENTAL
Intervention: 4% prilocaine hydrochloride spray
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1.1% dipucaine ointment
Number of subjects: 40
Study: 3698654

Group type: EXPERIMENTAL
Intervention: Controlled-release diazepam (10 mg)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Controlled-release diazepam (15 mg)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 30247074

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid 500 mg every 6 hours for the first three days of menstruation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral micronised flavonoids 500 mg every 6 hours for the first three days of menstruation
Number of subjects: 100
Study: 27146615

Group type: COMPARATOR
Intervention: Fentanyl (1 µg/kg) and propofol
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Paracetamol (20 mg/kg) and propofol
Number of subjects: 146
Study: 23832323

Group type: EXPERIMENTAL
Intervention: Deltoid activation in rotator cuff tear patients preoperatively
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Deltoid activation in rotator cuff tear patients postoperatively
Number of subjects: 55

Group type: COMPARATOR
Intervention: Deltoid activation in controls with large abduction moment loading
Number of subjects: 55
Study: 22758930

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) and elements of the Bobath concept
Number of subjects: 84

Group type: COMPARATOR
Intervention: Traditional kinesiotherapy
Number of subjects: 84
Study: 19967335

Group type: EXPERIMENTAL
Intervention: Unidirectional locking plates
Number of subjects: 40

Group type: COMPARATOR
Intervention: Multidirectional locking plates
Number of subjects: 40
Study: 18237578

Group type: EXPERIMENTAL
Intervention: Dietary factors including fiber, phytostanols/phytosterols, n‐3 fatty acids, Mediterranean diet, and other plant‐based approaches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saturated fatty acids, trans‐fatty acids, and cholesterol
Number of subjects: 0
Study: 15616863

Group type: EXPERIMENTAL
Intervention: Metric tone sequences (higher-order, periodic structure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heavy beat tone sequences
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irregular tone sequences
Number of subjects: 0

Group type: COMPARATOR
Intervention: Light beat tone sequences (absent accents)
Number of subjects: 0
Study: 12772581

Group type: EXPERIMENTAL
Intervention: 0.5% chitosan mouthrinse for 14 days, rinsing with 20 ml twice daily for 30 seconds
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 24
Study: 10713862

Group type: EXPERIMENTAL
Intervention: Meropenem (500 mg every 8 h)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (1,000 mg every 12 h)
Number of subjects: 144
Study: 7499650

Group type: EXPERIMENTAL
Intervention: 3 percent mepivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4 percent prilocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2 percent lidocaine plus 1:100,000 epinephrine
Number of subjects: 60
Study: 2021719

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus fentanyl
Number of subjects: 85

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 85
Study: 6123760

Group type: EXPERIMENTAL
Intervention: Regular cuff (12 X 23 cm)
Number of subjects: 1240

Group type: COMPARATOR
Intervention: Three standard adult cuff sizes
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Formulae and a table for correction
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Hypertension prevalence estimation
Number of subjects: 1240
Study: 31981279

Group type: EXPERIMENTAL
Intervention: Plateletcrit (PCT)
Number of subjects: 567
Study: 31054140

Group type: EXPERIMENTAL
Intervention: RNA sequencing and transcriptomic analysis of sclerotial development
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative real‐time reverse transcription PCR validation of gene expression profiles
Number of subjects: 0
Study: 29122067

Group type: EXPERIMENTAL
Intervention: Biodentine™
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 32
Study: 26086066

Group type: EXPERIMENTAL
Intervention: Tomato juice (330 ml/d) for 20 days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Water (control group) for 20 days
Number of subjects: 75
Study: 23841265

Group type: COMPARATOR
Intervention: Chinese medicine treatment group (Group B) - FGG
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (Group A) - Voltaren Tablet
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ozone group (Group C) - Ozone injection (10-18 mL, 25 mg/L, once weekly for 4 weeks)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Chinese medicine treatment plus ozone group (Group D) - FGG and ozone injection
Number of subjects: 200
Study: 20653988

Group type: EXPERIMENTAL
Intervention: Validated mortality risk score
Number of subjects: 69
Study: 19339779

Group type: EXPERIMENTAL
Intervention: Combination of galantamine and memantine
Number of subjects: 2113

Group type: COMPARATOR
Intervention: Galantamine alone
Number of subjects: 2113
Study: 16696459

Group type: EXPERIMENTAL
Intervention: OS-based features from tumor regions
Number of subjects: 84

Group type: COMPARATOR
Intervention: OS-based features from normal tissue regions
Number of subjects: 84
Study: 15297790

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) treatment (16-32 mg/kg/day) for 6 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33
Study: 12199273

Group type: EXPERIMENTAL
Intervention: DHEA replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 0
Study: 9699744

Group type: EXPERIMENTAL
Intervention: Folate intake (450 or 850 microg/day) provided as food folate (120 microg/day) and supplemental folic acid (330 or 730 microg/day) for 12 weeks
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (nonpregnant women)
Number of subjects: 2
Study: 7911921

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive-pressure ventilation (NIPPV) for at least 6 hours nocturnally (n = 35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional treatment (n = 35)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive-pressure ventilation (NIPPV)
Number of subjects: 70
Study: 2589383

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg) alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg) + Clindamycin (600 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg) + Metronidazole (500 mg)
Number of subjects: 10
Study: 1089875

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid, 750 mg per day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Phenobarbital, 180 mg per day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of chenodeoxycholic acid and phenobarbital
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7399948

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31935028

Group type: EXPERIMENTAL
Intervention: Osocimab 0.3 mg/kg postoperative (n=107)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Osocimab 0.6 mg/kg postoperative (n=65)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Osocimab 1.2 mg/kg postoperative (n=108)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Osocimab 1.8 mg/kg postoperative (n=106)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Osocimab 0.3 mg/kg preoperative (n=109)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Osocimab 1.8 mg/kg preoperative (n=108)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily (n=105)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Apixaban 2.5 mg twice daily (n=105)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Osocimab 0.6 mg/kg postoperative
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Osocimab 1.2 mg/kg postoperative
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Osocimab 1.8 mg/kg postoperative
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Osocimab 1.8 mg/kg preoperative
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Osocimab 0.3 mg/kg postoperative
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Osocimab 0.3 mg/kg preoperative
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Osocimab
Number of subjects: 813

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 813

Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 813
Study: 31208927

Group type: EXPERIMENTAL
Intervention: Music therapy during recovery (intervention group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 56
Study: 29407718

Group type: EXPERIMENTAL
Intervention: Behavior therapy (CBIT, Comprehensive Behavioral Intervention for Tics)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychoeducation plus supportive therapy (PST)
Number of subjects: 0
Study: 27008620

Group type: EXPERIMENTAL
Intervention: Real rTMS to the left DLPFC
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60